(CercleFinance.com) – Pherecydes Pharma announces that it has obtained authorization from the French ANSM to carry out a phase I / II clinical study, PhagoDAIR, in the treatment of osteoarticular infections on prostheses caused by Staphylococcus aureus.
This first phage therapy study in the world conducted in this indication will be conducted in France and Spain on 60 patients. It aims to assess the efficacy and tolerance of phages in association with the DAIR surgical intervention procedure.
The company plans to initiate patient recruitment in the spring of 2022, after approval by the People Protection Committee in January. The results are expected in summer 2023 and monitoring will continue until the first half of 2025.
Copyright © 2021 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
